A previous study showed that type I, but not type II, IFNs contribute to chemotherapy-induced ICD, and exogenous supplementation with type I IFNs (co-administration of IFNα and IFNβ), but not type II (IFNγ), provokes the potential of cisplatin to induce ICD [20]. The gene discussed is IFNB1; the disease is impulse control disorder.